UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/045,842	10/26/2001	Michel J.N. Cormier	33392-754.201	2394
	7590 07/30/200 l Palmer & Dodge LLF	EXAMINER		
P.O. Box 55874			CAMERON, ERMA C	
Boston, MA 02205			ART UNIT	PAPER NUMBER
			1792	
			MAIL DATE	DELIVERY MODE
			07/30/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/045,842	CORMIER ET AL.		
Office Action Summary	Examiner	Art Unit		
	/Erma Cameron/	1792		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on 27 Ma	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 18-20,22-24,28-35,47 and 51-53 is/are 4a) Of the above claim(s) 28 is/are withdrawn fr 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 18-20,22-24,29-35,47 and 51-53 is/are 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	rom consideration. e rejected.			
Application Papers				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction of the order and the order access are considered. 11) The oath or declaration is objected to by the Examiner.	epted or b) objected to by the lidrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 4/28/2008.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate		

Application/Control Number: 10/045,842

Art Unit: 1792

DETAILED ACTION

Page 2

Response to Amendment

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 51 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

"...wherein the coating provides systemic delivery of about 25% to 50% of the agent upon application of the device to the skin of a subject for 5 seconds..." is new matter that was not in the specification as originally filed.

The specification does not support this statement as applied to <u>all</u> the active agents in the claimed invention.

[0061] [0064] [0066] [0071] and Figures 8-10 (cited by applicant for support) support:

[0061] 26% in 5 seconds for desmopressin

[0066] 50% in 5 seconds for hGH

[0071] >80% in 5 seconds for ovalbumin

Art Unit: 1792

The applicant is requested to cancel new matter.

3. Claim 53 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described

in the specification in such a way as to reasonably convey to one skilled in the relevant art that

the inventor(s), at the time the application was filed, had possession of the claimed invention.

See paragraph 2 above. 80% delivery in 5 seconds is not supported <u>for all</u> active agents in the claimed invention.

The applicant is requested to cancel new matter.

Claim Rejections - 35 USC § 103

4. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

5. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being

unpatentable over Szumski et al (3470011) is withdrawn because of the amendments and

arguments presented in the 3/27/2008 amendment.

Art Unit: 1792

6. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being unpatentable over Palmer (6537242) is withdrawn because of the amendments and arguments presented in the 3/27/2008 amendment.

- 7. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being unpatentable over Powell (6589202) is withdrawn because of the amendments and arguments filed 3/27/2008.
- 8. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being unpatentable over WO 96/10630 is withdrawn because of the amendments and arguments filed 3/27/2008.
- 9. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being unpatentable over Ginaven et al (5457041) is withdrawn because of the amendment and arguments filed 3/27/2008.
- 10. The rejection of Claims 18-24, 29-35 and 47 under 35 U.S.C. 103(a) as being unpatentable over Cormier et al (US2002 / 010292) is withdrawn because of the statement of common ownership filed 3/27/2008.

Art Unit: 1792

Double Patenting

12. The text of those sections of Title 35, U.S. Code not included in this action can be found

in a prior Office action.

13. Claims 18-20, 22-24, 29-35, 47 and 51-53 are provisionally rejected under the judicially

created doctrine of obviousness-type double patenting as being unpatentable over claims 54-64

of copending Application No. 11/034,891.

As outlined in the previous office action, although the conflicting claims are not identical,

they are not patentably distinct from each other because the Application teaches the limitations

of the claims and only fails to teach the dose, solubility, and viscosity of the agent of the instant

claims. However, claims in the 11/034,891 application are directed to the same active agents as

the claims and specification of the instant application, which would inherently be useful in the

same dosage, solubility, and viscosity as instantly claimed.

This is a provisional obviousness-type double patenting rejection because the conflicting

claims have not in fact been patented.

14. Claims 18-20, 22-24, 29-35, 47 and 51-53 are provisionally rejected on the ground of

nonstatutory obviousness-type double patenting as being unpatentable over claims 28-54 of

Art Unit: 1792

copending Application No. 10/127108, over claims 21-39 of copending Application No. 10/674626, over claims 10-13 of copending Application No. 10/972231, over claims 33-38 of copending Application No. 11/201625, over claims 32-34 of copending Application no. 11/206698 and over claims 30-35 of copending Application No. 11/355856.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the coatings on the microprotrusions of the Applications are merely variations of and included in the "pharmacologically active agent" of the instant application.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

15. The applicant has asked that the double patenting rejections be stayed until subject matter is indicated to be allowable. This is being done.

Declaration under 37 CFR 1.132

16. The 1.132 Declaration under 37 CFR 1.132 filed 3/27/2008 is sufficient to overcome the rejection of claims 18-24, 29-35 and 47 based upon the prior art as indicated above.

Art Unit: 1792

Conclusion

17. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to /Erma Cameron/ whose telephone number is 571-272-1416. The examiner can normally be reached on Monday through Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks can be reached on 571-272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1792

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Erma Cameron/ Primary Examiner Art Unit 1792

July 21, 2008